ESMO 2024: Treatment Breakthroughs in Pretreated Patients with Advanced or Metastatic NSCLC With or Without Actionable Genomic Alterations - Episode 3

ADAURA Trial Findings: Outcomes and CNS Involvement in EGFR-Mutated NSCLC

, , , ,

This episode reviews the key takeaways from the ADAURA trial, discusses strategies for protecting the CNS in EGFR-mutated NSCLC, and examines the impact ADAURA had on recurrence rates in patients with completely resected EGFR-mutated NSCLC who were previously treated with adjuvant chemotherapy.

Video content above is prompted by the following:

  • Comment on the key takeaways from the ADAURA trial.
  • What are your thoughts on protecting the CNS?
  • In your experience, what is the average disease recurrence rate among patients with completely resected EGFR-mutated early or locally advanced NSCLC treated with adjuvant chemotherapy alone? What was your experience prior to ADAURA, and how has ADAURA changed that since?